1H24 highlights: RedHill Biopharma (Nasdaq: RDHL) with numerous potential catalysts a strengthened cash balance and low cost-base, maintaining Talicia’s leadership position, a promising, financially de-risked pipeline, backed by multiple U.S. government collaborations. Read the RedHill PR: https://bit.ly/4dERHTP
RedHill Biopharma Ltd.
Pharmaceutical Manufacturing
Raleigh, NC 6,446 followers
RedHill (NASDAQ: RDHL): a pharmaceutical company focused on proprietary drugs for GI and infectious diseases
About us
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development. RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification. RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
- Website
-
http://www.redhillbio.com/
External link for RedHill Biopharma Ltd.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Raleigh, NC
- Type
- Public Company
- Founded
- 2009
Locations
-
Primary
Get directions
8045 Arco Corporate Drive
Suite 120
Raleigh, NC 27617, US
-
Get directions
21 Ha’arba’a St.
Tel-Aviv , Israel 6473921, IL
Employees at RedHill Biopharma Ltd.
-
Gilead Raday
-
Rob Cohen
Sr. Director, Communications, RedHill Biopharma Ltd.
-
Steven Thomasian
Vice President Supply Chain @ RedHill Biopharma | Strategic Sourcing, Process Improvement, Cost Savings and Commercial Launches
-
Alexandra Okmian Sanderovich
Senior Business Development and Investor Relations Manager at RedHill Biopharma Ltd.
Updates
-
RedHill Biopharma’s (Nasdaq: RDHL) opaganib granted FDA orphan-drug status for neuroblastoma, the most common infant malignancy accounting for 15% of pediatric cancer deaths. Broad oncology potential & 7-years exclusivity. Read the RedHill PR: https://bit.ly/3YTrJHQ
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
redhillbio.com
-
RedHill Biopharma’s (Nasdaq: RDHL) Talicia launched in the United Arab Emirates (UAE) triggering RedHill’s eligibility for additional potential milestone payments, minimum sales payments and tiered royalties. Read the RedHill PR: https://bit.ly/46Ty73Q
Talicia® Launched in the United Arab Emirates
redhillbio.com
-
RedHill Biopharma’s (Nasdaq: RDHL) opaganib delivers positive in vivo results in metabolic disease models supporting potential use in diabetes and obesity-related disorders. Read the RedHill PR: https://bit.ly/3YLlOob
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
redhillbio.com
-
New publication in the peer reviewed journal, Antibiotics, of ground-breaking positive data from RedHill Biopharma’s (Nasdaq: RDHL) Phase 3 Crohn’s disease study with RHB-104. Data shows that treatment with RHB-104 plus standard of care (SoC) was 64% more effective than SoC alone, meeting the study’s primary endpoint with high statistical significance. Read the RedHill PR: https://bit.ly/3ylRFkt
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
redhillbio.com
-
RedHill Biopharma (Nasdaq: RDHL) strengthens cash balance, settles obligations and removes Talicia® lien through a Termination Agreement with Movantik Acquisition Co. and related parties: Red the RedHill PR: https://bit.ly/4fdtoNV
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
redhillbio.com
-
RedHill Biopharma (Nasdaq: RDHL), in agreement with Cosmo Pharmaceuticals, terminates the license agreement for Aemcolo®. Read the RedHill PR: https://bit.ly/45Vo3GQ
RedHill Biopharma Terminates License Agreement for Aemcolo®
redhillbio.com
-
RedHill Biopharma (Nasdaq: RDHL) announces new Chinese patent covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response, valid until 2040. Read the RedHill PR here: https://bit.ly/3yWiCeg
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
redhillbio.com
-
RedHill Biopharma (Nasdaq: RDL) announces new Chinese patent for opaganib for the treatment of Ebola Disease Virus, valid through 2035. Read the RedHill PR: https://bit.ly/4dm9Q9r
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
redhillbio.com
-
RedHill Biopharma (Nasdaq: RDHL) announces that the first patient has been enrolled in the U.S. Government-supported multinational platform study of RHB-107 for early COVID-19 outpatient treatment. Read the RedHill PR: https://bit.ly/3xZLPVd
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
redhillbio.com